Analyst Ratings for Regeneron Pharmaceuticals Inc. (REGN)Updated: 2017-07-28
Analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have given it a consensus rating of Overweight. A consensus rating of Overweight was previously issued for REGN last month.
Of the 24 analysts covering the stock, 10 gave it a buy rating, 1 issued an overweight rating, 13 gave a hold rating, 0 gave an underweight rating, and 0 gave a sell rating. Compared to three months ago, there has been an decrease of 3 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.
Several price targets were given for REGN by the analysts covering the stock. The most optimistic analyst gave a price target of 593, implying potential capital gains of 16.64 percent. The lowest price target was 327, which equates to a potential downside of -35.68 percent. It is crucial to not blindly accept any price targets or stock ratings, because many analysts have it in their best interest to give positive coverage of certain stocks.
In the last 30 days, analysts have changed their quarterly earnings estimates upwards by an average of 0.48 percent. That number becomes -0.14 percent if we expand the time horizon to include the past 3 months instead of just one. Over the past 30 days, FY earnings estimates have also changed upwards by 0.39 percent. If we look at the last 90 days instead, we find a net average change of 0.77 percent in FY estimates.
People are often interested in whether analysts were united in the direction of their revisions. 1 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 0 analysts that decreased their estimates. Also over the last month, 1 analysts increased their estimates for the FY earnings, compared to 0 analysts that revised their FY estimates downwards.
REGN has an estimated earnings growth rate of 24.83 percent as forecasted by analysts. People on Wall Street often look at a company's PEG ratio. A lower PEG ratio is favorable, because people typically see that as an indicator of higher growth relative to stock price. Wall Street investors typically prefer a PEG ratio to be smaller than 1, though it could be better to see where the ratio stands relative to peers in the industry. REGN has a PEG ratio of 2.46.
In the trailing 52-weeks, REGN hit 543.55 at the highest peak, while it's lowest trading point was 325.35. Currently the stock is 56.27 percent higher than its low, and 6.46 percent lower than its 52-week high. REGN has a price/earnings ratio of 61.18. Investors typically compare the P/E ratio to a company's peers in the industry. The REGN value stock report compares REGN to some of its peers using value stock charts. The stock has a market capitalization of $54.81 billion. REGN's next earnings release will be on 0000-00-00, which is days away.